317 related articles for article (PubMed ID: 33667684)
1. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
2. Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development.
Zhou E; Hoeke G; Li Z; Eibergen AC; Schonk AW; Koehorst M; Boverhof R; Havinga R; Kuipers F; Coskun T; Boon MR; Groen AK; Rensen PCN; Berbée JFP; Wang Y
Cardiovasc Res; 2020 Aug; 116(10):1710-1720. PubMed ID: 31589318
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Hoeke G; Wang Y; van Dam AD; Mol IM; Gart E; Klop HG; van den Berg SM; Pieterman EH; Princen HMG; Groen AK; Rensen PCN; Berbée JFP; Boon MR
Atherosclerosis; 2017 Dec; 267():116-126. PubMed ID: 29121499
[TBL] [Abstract][Full Text] [Related]
4. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
5. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.
Liu C; Schönke M; Zhou E; Li Z; Kooijman S; Boon MR; Larsson M; Wallenius K; Dekker N; Barlind L; Peng XR; Wang Y; Rensen PCN
Cardiovasc Res; 2022 Jan; 118(2):489-502. PubMed ID: 33693480
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway.
Ying Z; van Eenige R; Beerepoot R; Boon MR; Kloosterhuis NJ; van de Sluis B; Bartelt A; Rensen PCN; Kooijman S
Pharmacol Res; 2023 Jan; 187():106634. PubMed ID: 36574856
[TBL] [Abstract][Full Text] [Related]
10. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
[TBL] [Abstract][Full Text] [Related]
11. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Landlinger C; Pouwer MG; Juno C; van der Hoorn JWA; Pieterman EJ; Jukema JW; Staffler G; Princen HMG; Galabova G
Eur Heart J; 2017 Aug; 38(32):2499-2507. PubMed ID: 28637178
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Kühnast S; van der Hoorn JW; Pieterman EJ; van den Hoek AM; Sasiela WJ; Gusarova V; Peyman A; Schäfer HL; Schwahn U; Jukema JW; Princen HM
J Lipid Res; 2014 Oct; 55(10):2103-12. PubMed ID: 25139399
[TBL] [Abstract][Full Text] [Related]
13. Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic-Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies.
Nolain P; Djebli N; Brunet A; Fabre D; Khier S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):789-802. PubMed ID: 35974290
[TBL] [Abstract][Full Text] [Related]
14. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
[TBL] [Abstract][Full Text] [Related]
15. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
[TBL] [Abstract][Full Text] [Related]
16. CETP expression reverses the reconstituted HDL-induced increase in VLDL.
Wang Y; Berbée JF; Stroes ES; Smit JW; Havekes LM; Romijn JA; Rensen PC
J Lipid Res; 2011 Aug; 52(8):1533-41. PubMed ID: 21606464
[TBL] [Abstract][Full Text] [Related]
17. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
[TBL] [Abstract][Full Text] [Related]
18. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
19. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.
Pouwer MG; Pieterman EJ; Worms N; Keijzer N; Jukema JW; Gromada J; Gusarova V; Princen HMG
J Lipid Res; 2020 Mar; 61(3):365-375. PubMed ID: 31843957
[TBL] [Abstract][Full Text] [Related]
20. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
